Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally. 

There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.

In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

The next frontier for cell therapy is solid tumors – and of the many attempts to move from liquid to solid tumors, tumor infiltrating lymphocytes and other CAR-T constructs are some of the most promising.